OM:ISR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

ISR Immune System Regulation Holding

Executive Summary

ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has ISR Immune System Regulation Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.7%

ISR

-0.3%

SE Biotechs

1.8%

SE Market


1 Year Return

16.6%

ISR

23.3%

SE Biotechs

19.7%

SE Market

Return vs Industry: ISR underperformed the Swedish Biotechs industry which returned 24.7% over the past year.

Return vs Market: ISR underperformed the Swedish Market which returned 21.6% over the past year.


Shareholder returns

ISRIndustryMarket
7 Day0.7%-0.3%1.8%
30 Day-7.9%-0.6%2.2%
90 Day98.0%17.7%23.1%
1 Year16.6%16.6%24.2%23.3%21.5%19.7%
3 Year-2.3%-3.4%46.6%42.8%33.4%19.4%
5 Yearn/a88.1%75.1%53.5%23.2%

Price Volatility Vs. Market

How volatile is ISR Immune System Regulation Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ISR Immune System Regulation Holding undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether ISR Immune System Regulation Holding is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ISR Immune System Regulation Holding has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ISR's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through ISR Immune System Regulation Holding regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is ISR Immune System Regulation Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ISR Immune System Regulation Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of ISR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • ISR Immune System Regulation Holding competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has ISR Immune System Regulation Holding performed over the past 5 years?

-38.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ISR is currently unprofitable.

Growing Profit Margin: ISR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ISR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.4%).


Return on Equity

High ROE: ISR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is ISR Immune System Regulation Holding's financial position?


Financial Position Analysis

Short Term Liabilities: ISR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ISR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ISR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ISR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ISR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is ISR Immune System Regulation Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISR's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Ola Winqvist (58 yo)

2.58yrs

Tenure

Professor Ola S. Winqvist, MD, PhD is Chief Executive Officer of ISR Immune System Regulation Holding AB (publ) since 2019. He has been a Member of Scientific Board at Oncimmune Holdings Plc since December ...


Leadership Team

NamePositionTenureCompensationOwnership
Ola Winqvist
Chief Executive Officer2.58yrsno datano data
Gunnar Jardelöv
Co-Founder & Director4.58yrsno datano data
Gunnar Modalen
Chief Financial Officer3.58yrsno datano data
Lennart Dreyer
3.58yrsno datano data

3.6yrs

Average Tenure

62.5yo

Average Age

Experienced Management: ISR's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gunnar Jardelöv
Co-Founder & Director4.58yrsno datano data
Anders Milton
Chairman of the Board4.58yrsno data4.32%
SEK 6.5m
Hans Glise
Director3.58yrsno datano data

4.6yrs

Average Tenure

73yo

Average Age

Experienced Board: ISR's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ISR Immune System Regulation Holding AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ISR Immune System Regulation Holding AB (publ)
  • Ticker: ISR
  • Exchange: OM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr149.298m
  • Shares outstanding: 24.72m
  • Website: https://israb.se

Location

  • ISR Immune System Regulation Holding AB (publ)
  • Rörstrandsgatan 58
  • Stockholm
  • Stockholm County
  • 113 40
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISROM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMar 2017
5JKDB (Deutsche Boerse AG)YesShare CapitalDEEURMar 2017

Biography

ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company’s product candidates include ISR048 that has completed Phase I/IIa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/15 03:08
End of Day Share Price2020/08/14 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.